Sablich Kim
Known title: EVP & GM, North AmericaCIK: 0001758790
Associated companies
Transaction History
| JAZZ | ▼ Sell | Other | 2,082 | $270K | 6/5/2023 | View on chart |
| JAZZ | ▼ Sell | Open Market | 1,752 | $244K | 3/8/2023 | View on chart |
| JAZZ | ▼ Sell | Open Market | 1,261 | $177K | 3/8/2023 | View on chart |
| JAZZ | ▼ Sell | Tax Withholding | 1,610 | $230K | 3/5/2023 | View on chart |
| JAZZ | ▲ Buy | Grant | 10,429 | $0 | 3/3/2023 | View on chart |
| JAZZ | ▼ Sell | Open Market | 200 | $30K | 6/7/2022 | View on chart |
| JAZZ | ▼ Sell | Open Market | 250 | $37K | 6/7/2022 | View on chart |
| JAZZ | ▼ Sell | Open Market | 573 | $86K | 6/7/2022 | View on chart |
| JAZZ | ▼ Sell | Open Market | 1,317 | $200K | 6/7/2022 | View on chart |
| JAZZ | ▼ Sell | Open Market | 101 | $15K | 6/7/2022 | View on chart |
| JAZZ | ▼ Sell | Tax Withholding | 1,759 | $263K | 6/6/2022 | View on chart |
| JAZZ | ▼ Sell | Open Market | 1,388 | $211K | 6/6/2022 | View on chart |
| JAZZ | ▼ Sell | Tax Withholding | 746 | $115K | 3/5/2022 | View on chart |
| JAZZ | ▲ Buy | Grant | 9,953 | $0 | 3/3/2022 | View on chart |
| JAZZ | ▼ Sell | Open Market | 2,748 | $371K | 11/11/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
JAZZ: Ziihera FDA win and leadership change shift company outlook
Jazz Pharmaceuticals recently received FDA approval for Ziihera and underwent a leadership change, which analysts suggest may alter the investment case. The company is also diversifying its portfolio, changing the narrative around its earnings. While the stock is currently trading near its 52-week low, the average analyst target price remains significantly higher than the current market level.
JAZZ: Ziihera FDA win and leadership change shift company outlook. Jazz Pharmaceuticals recently received FDA approval for Ziihera and underwent a leadership change, which analysts suggest may alter the investment case. The company is also diversifying its portfolio, changing the narrative around its earnings. While the stock is currently trading near its 52-week low, the average analyst target price remains significantly higher than the current market level.